Hangzhou Polymed Biopharmaceuticals Inc. has divulged molecular glue degraders comprising cereblon (CRBN) binding agents covalently bound to a zinc finger protein Helios (IKZF2)-targeting moiety acting as IKZF2 degradation and IKZF2/CRBN interaction inducers.
Bristol Myers Squibb Co. has identified serum/glucocorticoid-regulated kinase 1 (SGK1) inhibitors reported to be useful for the treatment of fibrosis, cancer, cardiovascular, cerebrovascular, metabolic, inflammatory, neurological and immunological disorders, among others.
Isosterix Inc. has synthesized histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.
Hangzhou Synrx Therapeutics Technology Co. Ltd. has disclosed poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of triple-negative breast cancer.
Bayer AG has identified α2C-adrenoceptor antagonists reported to be useful for the treatment of dysphagia, snoring, neurodegeneration, neuroinflammation and cardiovascular disorders.
Neushen Therapeutics Inc. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune disease, cardiovascular disorders, neurodegeneration and chronic obstructive pulmonary disease.